Produktname:1-(3-bromo-4-ethylphenyl)ethanone
IUPAC Name:1-(3-bromo-4-ethylphenyl)ethan-1-one
- CAS：90841-42-2
- Molekulare Formel：C10H11BrO
- Reinheit：95%+
- Katalognummer：CM588910
- Molekulargewicht：227.1
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:90841-42-2
- Molekulare Formel:C10H11BrO
- Schmelzpunkt:-
- SMILES-Code:CCC1=C(C=C(C=C1)C(=O)C)Br
- Dichte:
- Katalognummer:CM588910
- Molekulargewicht:227.1
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Column Infos
- Alectinib
- Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Suche 
+86 21 5895 0110 
